arrow
S

Sharon Sand

university of pittsburgh
H指数:18
被引数:1,999

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America
2021-08-1917
OAAI
Breast cancer associated pathogenic variants among women 61 years and older with triple negative breast cancer
2021-06-018
OAAI
Germline mutations and age at onset of lung adenocarcinoma

肺腺癌发病时的种系突变和年龄

CANCER
IF5.1
2021-04-1517
OAAI
Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition
2020-05-017
OAAI
Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer
CANCER
IF5.1
2019-06-1744
OAAI
Prospective Study of Cancer Genetic Variants: Variation in Rate of Reclassification by Ancestry

癌症遗传变异的前瞻性研究: 按血统重新分类的比率的变化

2018-04-0153
OAAI
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
2017-08-0185
OAAI
Evaluation of the BOADICEA model for predicting BRCA1 and BRCA2 mutation carrier probabilities in high-risk US Hispanic and Mexican families: A report from the Clinical Cancer Genetics Community Research Network
2015-08-010
PRE
Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

BRCA1突变携带者的全基因组关联研究确定了与乳腺癌和卵巢癌风险相关的新基因座

2013-03-27257
OAAI
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer

KRAS变体是不良结果,铂类化疗耐药的生物标志物,也是卵巢癌治疗的潜在靶点

2011-12-0563
OAAI